Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial

Journal of the American College of Cardiology

Volumn 36, Issue 4, 2000, Pages 1239-1244

  Lazarous, Daisy F ^a,c   Unger, Ellis F ^a   Epstein, Stephen E ^a   Stine, Annette ^a   Arevalo, Josefino L ^a   Chew, Emily Y ^b   Quyyumi, Arshed A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; PLACEBO;

ADULT; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMORAL ARTERY; FEMORAL ARTERY FLOW; GASTROCNEMIUS MUSCLE; HUMAN; INTERMITTENT CLAUDICATION; MALE; NEOVASCULARIZATION (PATHOLOGY); PHASE 1 CLINICAL TRIAL; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANKLE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTOR 2; HALF-LIFE; HUMANS; INJECTIONS, INTRA-ARTERIAL; INTERMITTENT CLAUDICATION; MALE; PLETHYSMOGRAPHY; SAFETY;

EID: 0033820196     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00882-2     Document Type: Article

References (29)

1. Peripheral vascular disease: A public health perspective
2. Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965-1985
3. Intermittent claudication. A risk profile from the Framingham Heart study
4. Epidemiology of peripheral arterial disease
5. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: Results from noninvasive testing in a defined population
6. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
7. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart
8. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
9. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor
10. Basic fibroblast growth factor increases collateral blood flow in rats with femoral artery ligation
11. Enhanced angiogenesis and growth of collaterals by in vivo administration of basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor
12. bFGF enhances the development of the collateral circulation after acute arterial occlusion
13. Progressive vs. single-stage treadmill tests for evaluation of claudication
14. The measurement of volume changes in human limb
15. Safety of direct myocardial VEGF-121 cDNA adenovirus-mediated angiogenesis gene therapy in conjunction with coronary bypass surgery
16. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty. Safety Results from Phase I Kuopio Angioplasty Gene Transfer Trial (KAT Trial)
17. 165 as sole therapy for myocardial ischemia
18. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor - The VIVA trial
19. Induction of neoangiogenesis in ischemic myocardium by human growth factors
20. Intracoronary administration of recombinant fibroblast growth factor-2 in patients with severe coronary artery disease: Results of phase I
21. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery. Results of a Phase I randomized, double-blind, placebo-controlled trial
22. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
23. Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis
24. Preclinical and clinical studies with recombinant human basic fibroblast growth factor
25. Factors controlling ocular angiogenesis
26. The role of growth factors in the development of diabetic retinopathy
27. Hypotensive activity of fibroblast growth factor
28. Pharmacologic vasodilators in the coronary circulation
29. Collateral perfusion: The role of endothelium-derived relaxing factor and effects of vasodilators